FPI-2265 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-23 in 3mo
ESTIMATED |
READOUT
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-
Phase 2 · Metastatic Castration-resistant Prostate Cancer |
Fusion Pharmaceuticals Inc. | FPI-2265 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|